"That patient group" is 2/3 of the GBM patients. Additionally, the 1/3 of patients Temo does work in develop resistance to it.
With a low GI diet, Pax will work even better. (See Dr. Dun's recent remarks)
I have no idea how you could be disappointed if you understand what the implications are.
- Forums
- ASX - By Stock
- KZA
- Ann: Kazia releases final data from P2 paxalisib trial
Ann: Kazia releases final data from P2 paxalisib trial, page-14
-
- There are more pages in this discussion • 94 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)